期刊
VIRUSES-BASEL
卷 15, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/v15030687
关键词
COVID-19; SARS-CoV-2; Omicron variant; BA; 5; 2; XBB; 1; Fc-RBD; CoronaVac; neutralizing antibody
类别
The development of vaccines specific against the dominant circulating strains of SARS-CoV-2 is being outpaced by the emergence of new immune-evasive variants and subvariants. In this study, researchers explored the hypothesis that intranasal boosting after intramuscular priming could provide a broader level of protection. They found that intranasal boosts with the Fc-linked trimeric spike receptor-binding domain from wild-type SARS-CoV-2 induced significantly higher serum neutralizing antibodies against wild-type SARS-CoV-2 and the Omicron subvariants, compared to vaccination with the inactivated whole virion vaccine. This approach could potentially lengthen the interval required for changing the vaccine immunogen from months to years.
The emergence of new immune-evasive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and subvariants outpaces the development of vaccines specific against the dominant circulating strains. In terms of the only accepted immune correlate of protection, the inactivated whole-virion vaccine using wild-type SARS-CoV-2 spike induces a much lower serum neutralizing antibody titre against the Omicron subvariants. Since the inactivated vaccine given intramuscularly is one of the most commonly used coronavirus disease 2019 (COVID-19) vaccines in developing regions, we tested the hypothesis that intranasal boosting after intramuscular priming would provide a broader level of protection. Here, we showed that one or two intranasal boosts with the Fc-linked trimeric spike receptor-binding domain from wild-type SARS-CoV-2 can induce significantly higher serum neutralizing antibodies against wild-type SARS-CoV-2 and the Omicron subvariants, including BA.5.2 and XBB.1, with a lower titre in the bronchoalveolar lavage of vaccinated Balb/c mice than vaccination with four intramuscular doses of inactivated whole virion vaccine. The intranasally vaccinated K18-hACE2-transgenic mice also had a significantly lower nasal turbinate viral load, suggesting a better protection of the upper airway, which is the predilected site of infection by Omicron subvariants. This intramuscular priming and intranasal boosting approach that achieves broader cross-protection against Omicron variants and subvariants may lengthen the interval required for changing the vaccine immunogen from months to years.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据